Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials
GM Iannantuono, E Chandran, CS Floudas… - Cancer Treatment …, 2023 - Elsevier
Introduction PARP inhibitors (PARPi) are a standard-of-care (SoC) treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …
patients with metastatic castration-resistant prostate cancer (mCRPC). Several clinical trials …
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Background Co-inhibition of poly (ADP-ribose) polymerase (PARP) and androgen receptor
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …
Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: A quantitative synthesis and meta-analysis
Context PARP inhibitors (PARPi) are established treatments for metastatic castration-
resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency …
resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency …
[HTML][HTML] First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
K Fizazi, AA Azad, N Matsubara, J Carles, AP Fay… - Nature medicine, 2024 - nature.com
Preclinical evidence has suggested an interplay between the androgen receptor, which
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …
[HTML][HTML] Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene …
Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …
Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology
EM Schaeffer, S Srinivas, N Adra, Y An… - Journal of the National …, 2023 - jnccn.org
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …
regarding the workup of patients with prostate cancer, risk stratification and management of …
Poly (adenosine diphosphate‐ribose) polymerase inhibitor combinations in first‐line metastatic castrate‐resistant prostate cancer setting: a systematic review and m …
Objectives To compare radiographic progression‐free survival (rPFS), overall survival (OS),
and treatment‐emergent adverse events (TEAEs) among patients with metastatic castrate …
and treatment‐emergent adverse events (TEAEs) among patients with metastatic castrate …
[HTML][HTML] PARP inhibitors for prostate cancer
O Longoria, N Beije, JS de Bono - Seminars in Oncology, 2023 - Elsevier
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment
landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and …
landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and …
[HTML][HTML] The biology behind combining PARP and androgen receptor inhibition for metastatic castration resistant prostate cancer
For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …
almost exclusively to treat tumors that are deficient in one of the BRCA genes. In advanced …
[HTML][HTML] Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
Prostate cancer (PCa) is the most common cancer in men worldwide. Despite better and
more intensive treatment options in earlier disease stages, a large subset of patients still …
more intensive treatment options in earlier disease stages, a large subset of patients still …